These observations suggest that platelets contribute to SARS-CoV-2-induced inflammation significantly, and blockade of CLEC5A and TLR2 may be beneficial to alleviate thromboinflammation and reduce intravascular coagulopathy in COVID-19 patients. The gene discussed is CLEC5A; the disease is COVID-19.